Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ronald Wooten Insider Profile
4 Followers
Ronald Wooten, Director, Ten Percent Owner at Revance Therapeutics, holds 5.00 shares in Aceragen (Ticker: ACGN), holds 3.10M shares in Revance Therapeutics (Ticker: RVNC).
Ronald Wooten has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Director, Ten Percent Owner
Roles that Ronald Wooten holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Ronald Wooten
Ronald Wooten's Trading History
Revance Therapeutics
Feb 11, 2014
Director, Ten Percent Owner
Uninformative Buy
―
$10.28M
Aceragen
Sep 30, 2022
―
Uninformative Buy
―
$1.90
List of latest transactions for each holding click on a transaction to see Ronald Wooten's performance on stock
You May Also Like
Ronald Wooten insider profile FAQ
What is the percentage of profitable transactions made by Ronald Wooten?
The percentage of profitable transactions made by Ronald Wooten is ―.
What is the average return per transaction made by Ronald Wooten?
The average return per transaction made by Ronald Wooten is ―.
What stocks does Ronald Wooten hold?
Ronald Wooten holds: RVNC, ACGN stocks.
What was Ronald Wooten’s latest transaction?
Ronald Wooten latest transaction was an Uninformative Buy of ―.
What was Ronald Wooten's most profitable transaction?
Ronald Wooten’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Ronald Wooten's role in Revance Therapeutics?
Ronald Wooten's role in Revance Therapeutics is Director, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.